Esperion Therapeutics Inc (ESPR) Annual Income Statement (USD)
ESPR Quarterly Financials (USD)
Frequently Asked Questions About Esperion Therapeutics Inc (ESPR) Stock
Esperion Therapeutics Inc's (ESPR) last reported annual revenue was USD 116.33 Million.
Esperion Therapeutics Inc's (ESPR) annual revenue growth rate based on the revenue reported in the past 5 years is : -8.81%
Esperion Therapeutics Inc's(ESPR) is not profitable as of its last reported annual financials.
The net profit margin for Esperion Therapeutics Inc's(ESPR) from its laster reported year is -179.87%
The return on equity (ROE) for Esperion Therapeutics Inc's(ESPR) from its last reported annual financials is : -260.79%
The return on assets (ROA) for Esperion Therapeutics Inc's(ESPR) from its last reported annual financials is : 3.84%
The return on invested capital (ROIC) for Esperion Therapeutics Inc's(ESPR) from its last reported annual financials is : 24.43%
The Debt to Equity ratio for Esperion Therapeutics Inc's(ESPR) from its last reported annual financials is : -57.49%
The dividend yield for Esperion Therapeutics Inc's(ESPR) from its laster reported year is 0.00%
Esperion Therapeutics Inc's(ESPR) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ESPR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
